DNA Vaccines Market: By Type (Animal DNA vaccine and Human DNA vaccine), By Application (Human disease and Veterinary disease), By Technology (Plasmid DNA vaccines and Plasmid DNA delivery) and Geography   

DNA Vaccines Market size is valued at USD 453.4 million in 2021 and is expected to grow at a CAGR of 6.6% during the forecast period 2022 to 2028. DNA vaccination is a method for shielding an individual against illness by vaccinating it with genetically engineered DNA, so cells directly manufacture an antigen, ensuing in a defensive immunological response. It contains delivering genes or fragments of it, training immunogenic antigens to the cells of the host by utilizing DNA plasmids as a vector. This method encourages both cell-mediated and humoral immune responses efficiently. DNA vaccines are third-generation vaccines precisely designed to overcome the unsolicited possessions of conventional vaccines. The surge in the vulnerability of the population to communicable diseases and the growth in a number of antibiotic-resistant pathogens have created the necessity for low-cost and effective vaccination, which would deliver immunity for a longer time period. The global market provides a detailed overview of the DNA Vaccines market size, and that can be segmented by type, by application, and by technology. By type, the DNA Vaccines market growth has been segmented into Animal DNA vaccine and Human DNA vaccine. The animal DNA vaccine segment is likely to be the significant growing segment in terms of type. Based on Application, the DNA Vaccines market is segmented into Human application and Veterinary applications. Among these, the Human application segment is expected to have a significant growing market during the forecast period 2022-2028. Based on the technology, the DNA Vaccines market is segmented Plasmid DNA vaccines and Plasmid DNA delivery. The Plasmid DNA Preparation delivery segment is expected to have a significant share in 2021. Key Development:

• In August 2021, the three-dose ZyCoV-D vaccine  protected against symptomatic disease in 66% of those vaccinated